Loading
A phase 1/2 trial of TORL-5-700 in non-Hodgkin lymphoma, run by TORL Biotherapeutics, LLC, now recruiting.
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT07439653 by TORL Biotherapeutics, LLC, with 155 participants planned, started 2026-03-31 and due to reach its primary completion in 2029-03-31. Interventions recorded: TORL-5-700, TORL-5-700 at MTD/RP2D and TORL-5-700 at MTD/RP2D in combination with another agent.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/